BIOTECHNOLOGY VALUE FUND L P 13D and 13G filings for Aclaris Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-02-14 10:30 am Sale |
2023-12-31 | 13G | Aclaris Therapeutics, Inc. ACRS |
BIOTECHNOLOGY VALUE FUND L P | 0 0.000% |
-3,360,941 (Position Closed) |
Filing |
| 2023-03-16 4:48 pm Purchase |
2023-03-06 | 13G | Aclaris Therapeutics, Inc. ACRS |
BIOTECHNOLOGY VALUE FUND L P | 3,360,941 5.000% |
84,398 (+2.58%) |
Filing |
| 2023-02-14 11:40 am Sale |
2022-12-31 | 13G | Aclaris Therapeutics, Inc. ACRS |
BIOTECHNOLOGY VALUE FUND L P | 3,276,543 4.900% |
-591,500 (-15.29%) |
Filing |
| 2022-01-24 5:23 pm Purchase |
2022-01-13 | 13G | Aclaris Therapeutics, Inc. ACRS |
BIOTECHNOLOGY VALUE FUND L P | 3,868,043 6.300% |
3,868,043 (New Position) |
Filing |